林业发展局批准Keyturda、Herceptin和化疗组合,用于治疗高级胃癌。 FDA approves Keytruda, Herceptin, and chemotherapy combo for advanced gastric cancers.

美国食品和药物管理局已全面批准使用Keytruda (布利祖马布) 与Herceptin (特拉斯图祖马布) 结合,并进行化疗,用于初步治疗表达PD- L1的先进的HER2- 阳性胃或胃食道结癌. The FDA has fully approved the use of Keytruda (pembrolizumab) combined with Herceptin (trastuzumab) and chemotherapy for the initial treatment of advanced HER2-positive gastric or gastroesophageal junction cancers that express PD-L1. 批准的依据是一项研究表明存活率提高,与安慰剂相比,答复率提高。 This approval is based on a study showing improved survival rates and higher response rates compared to placebo. 副作用与已知药物的副作用是一致的。 Side effects were consistent with those known for the drugs.